AstraZeneca (AZ) has agreed to acquire CinCor Pharma (CinCor) – a company which concentrates on developing novel treatments for hypertension and chronic kidney disease.
The addition of the company will increase AZ’s cardiorenal pipeline as it will include CinCor’s candidate drug, baxdrostat.
Baxdrostat is a selective, oral small molecule inhibitor of aldosterone synthase – the enzyme responsible for the synthesis of aldosterone in the adrenal gland – and can be used for blood pressure lowering in treatment-resistant hypertension.
The drug represents a potentially leading next-generation aldosterone synthase inhibitor as it is selective for aldosterone synthase and, critically, spares the cortisol pathway among humans.
There is also potential for combining baxdrostat with Farxiga – a move which upholds AZ’s strategy to provide benefits throughout cardiorenal diseases, especially where there is a high unmet medical need.
Marc de Garidel, chief executive officer of CinCor, reflected: “We are excited about the proposed acquisition of CinCor by AZ as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.”
He added: “CinCor is committed to ensuring a smooth transition of the development responsibilities to AZ a once the acquisition is consummated.”
Mene Pangalos, executive vice president BioPharmaceuticals R&D, AZ, concluded: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.
“Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”
by John Pinching
Source: pharmatimes.com
Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.
StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.
In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.
